Paroxetine Transfer into Breast Milk
Paroxetine transfers into breast milk at approximately 1-2% of the weight-adjusted maternal dose, making it one of the safest antidepressants for breastfeeding mothers.
Breast Milk Concentration Data
The most robust evidence demonstrates that paroxetine excretion into breast milk is minimal:
- Infant dose exposure: Studies consistently show that breastfed infants receive approximately 1.1-1.25% of the weight-adjusted maternal dose 1, 2
- Milk-to-plasma ratio: The mean M/P ratio ranges from 0.39 to 0.96 depending on measurement methodology 1
- Breast milk concentrations: Highly variable (2-101 ng/mL), with a notable gradient effect where hind milk contains higher concentrations than fore milk 3
Clinical Safety Profile
Paroxetine is considered safe during breastfeeding because infant exposure remains well below the 10% safety threshold 1. Key safety findings include:
- Undetectable infant serum levels: In multiple studies, paroxetine was either undetectable or below quantifiable limits (<4 μg/L) in infant plasma samples 1, 2, 3, 4
- No adverse effects: No unusual adverse effects were reported in any breastfed infants across all studies 1, 2, 3, 4
- Guideline support: American Family Physician guidelines specifically identify paroxetine and sertraline as the most commonly prescribed antidepressants during breastfeeding, noting that "antidepressants transfer in low concentrations into breast milk" 5
Comparative Context
A pooled analysis of multiple antidepressants found that paroxetine, along with nortriptyline and sertraline, usually produces undetectable infant plasma levels, making these preferred choices for breastfeeding women 6. This contrasts with fluoxetine, which produces elevated infant levels (>10% of maternal levels) in 22% of cases 6.
Important Caveats
While short-term safety data are reassuring, the evidence base has limitations:
- Most studies evaluated short-term exposure only
- Long-term neurodevelopmental outcomes in exposed infants require further investigation 2
- Individual variability exists, particularly related to maternal CYP2D6 metabolism status, though this appears less clinically significant for breastfeeding than for maternal dosing 7
The clinical bottom line: Paroxetine's 1-2% transfer rate into breast milk, combined with consistently undetectable infant serum levels and absence of reported adverse effects, supports its use as a first-line SSRI option for breastfeeding mothers requiring antidepressant therapy.